ISTO Technologies, Inc.   Report issue

For profit Phase 3
Founded: Hopkinton MA United States (1997)
Status: No NME R&D (1997)

Organization Overview

First Clinical Trial
2011
NCT01400607
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2012

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 3 Trials (1)

autologous culture chondrocytes (Carticel) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cartilage Diseases (Phase 3)

Intervertebral Disc Degeneration (Phase 2)

Wounds and Injuries (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 1